Apolipoprotein E polymorphism influences lipid phenotypes in Chinese families with familial combined hyperlipidemia

Circulation Journal

Volumn 70, Issue 12, 2006, Pages 1606-1610

  Pei, Wei Dong ^a,d   Zhang, Yan Hong ^b   Sun, Yu Hua ^a   Gu, Yu Chun ^c   Wang, Yan Fen ^b   Zhang, Chao Yang ^a   Zhang, Jian ^a   Liu, Li Sheng ^a   Hui, Ru Tai ^a   Liu, Yu Qing ^a   Yang, Yue Jin ^a  

^a Fuwai Heart Hospital   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d FUWAI HOSPITAL   (China)

Author keywords

ApoE; Familial combined hyperlipidemia; Genotypes

Indexed keywords

ACYLTRANSFERASE; APOLIPOPROTEIN A1; APOLIPOPROTEIN A4; APOLIPOPROTEIN C3; APOLIPOPROTEIN E; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHATIDYLCHOLINE; TRIACYLGLYCEROL;

ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CHINA; CHROMOSOME 19Q; CONTROLLED STUDY; DYSLIPOPROTEINEMIA; FAMILIAL HYPERLIPEMIA; GENE CLUSTER; GENETIC POLYMORPHISM; HUMAN; HYPERLIPIDEMIA; LABORATORY TEST;

ADOLESCENT; ADULT; APOLIPOPROTEINS E; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; FEMALE; HUMANS; HYPERLIPIDEMIA, FAMILIAL COMBINED; LIPOPROTEINS; MALE; MIDDLE AGED; PHENOTYPE; POLYMORPHISM, GENETIC;

EID: 33751424634     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.70.1606     Document Type: Article

References (39)

1. Davignon J, Gregg RE, Sing CF. Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis 1988; 8: 1-21.
2. Eichner JE, Dunn ST, Perveen G, Thompson DM, Stewart KE, Stroehla BC. Apolipoprotein E polymorphism and cardiovascular disease: A HuGE Review. Am J Epidemiol 2002; 155: 487-495.
3. Tasaki H, Miyamoto M, Kubara T, Kamezaki F, Tanaka S, Yamashita K, et al. Cross-over trial of intensive monotherapy with atorvastatin and combined therapy with atorvastatin and colestimide for Japanese familial hypercholesterolemia. Circ J 2006; 70: 14-20.
4. Kawashiri MA, Higashikata T, Nohara A, Kobayashi J, Inazu A, Koizumi J, et al. Efficacy of colestimide coadministered with atorvastatin in Japanese patients with heterozygous familial hypercholesterolemia (FH). Circ J 2005; 69: 515-520.
5. Wang XL, McCredie RM, Wilcken DE. Polymorphisms of the apolipoprotein E gene and severity of coronary artery disease defined by angiography. Arterioscler Thromb Vasc Biol 1995; 15: 1030-1034.
6. Okabe TA, Kishimoto C, Shimada K, Murayama T, Yokode M, Kita T. Effects of late administration of immunoglobulin on experimental atherosclerosis in apolipoprotein E-deficient mice. Circ J 2005; 69: 1543-1546.
7. Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 1990; 31: 545-548.
8. Hallman DM, Boerwinkle E, Saha N, Sandholzer C, Menzel HJ, Csazar A, et al. The apolipoprotein E polymorphism: A comparison of allele frequencies and effects in nine populations. Am J Hum Genet 1991; 49: 338-349.
9. Utermann G. Apolipoprotein E polymorphism in health and disease. Am Heart J 1987; 113: 433-440.
10. Gómez-Coronado, Alvarez JJ, Entrala A, Olmos JM, Herrera E, Lasuncion MA. Apolipoprotein E polymorphism in men and women from a Spanish population: Allele frequencies and influence on plasma lipids and apolipoproteins. Atherosclerosis 1999; 147: 167-176.
11. Dallongeville J, Roy M, Leboeuf N, Xhignesse M, Davignon J, Lussier-Cacan S. Apolipoprotein E polymorphism association with lipoprotein profile in endogenous hypertriglyceridemia and familial hypercholesterolemia. Arterioscler Thromb 1991; 11: 272-278.
12. Ferrieres J, Sing CF, Roy M, Davignon J, Lussier-Cacan S. Apolipoprotein E polymorphism and heterozygous familial hypercholesterolemia: Sex-specific effects. Arterioscler Thromb 1994; 14: 1553-1560.
13. Genest JJ Jr, Martin-Munley SS, McNamara JR, Ordovas JM, Jenner J, Myers RH, et al. Familial lipoprotein disorders in patients with premature coronary artery disease. Circulation 1992; 85: 2025-2033.
14. Pajukanta P, Nuotio I, Terwilliger JD, Porkka KV, Ylitalo K, Pihlajamaki J, et al. Linkage of familial combined hyperlipidemia to chromosome 1q21-23. Nat Genet 1998; 18: 369-373.
15. Pei W, Baron H, Muller-Myhsok B, Knoblauch H, Al-Yahyaee SA, Hui R, et al. Support for linkage of familial combined hyperlipidemia to chromosome 1q21-23 in Chinese and German families. Clin Genet 2000; 57: 29-34.
16. Pajukanta P, Lilja HE, Sinsheimer JS, Cantor RM, Lusis AJ, Gentile M, et al. Familial combined hyperlipidemia is associated with upstream transcription factor 1 (USF1). Nat Genet 2004; 36: 371-376.
17. Bredie SJ, Vogelaar JM, Demacker PN, Stalenhoef AF. Apolipoprotein E polymorphism influences lipid phenotypic expression, but not the low density lipoprotein subfraction distribution in familial combined hyperlipidemia. Atherosclerosis 1996; 126: 313-324.
18. McNeely MJ, Edwards KL, Marcovina SM, Brunzell JD, Motulsky AG, Austin MA. Lipoprotein and apolipoprotein abnormalities in familial combined hyperlipidemia: A 20-year prospective study. Atherosclerosis 2001; 159: 471-481.
19. Goldstein JL, Schrott HG, Hazzard WR, Bierman EL, Motulsky AG. Hyperlipidemia in coronary heart disease. II: Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest 1973; 52: 1544-1568.
20. Friedewald WT, Levy RI, Fredrickson DS. Friedewald formula: Estimation of the concerntration of low density lipoprotein cholesterol in plasma without the use of preparative ultracentrifugation. Clin Chem 1972; 18: 499-502.
21. Richard P, Thomas G, de Zulueta MP, De Gennes JL, Thomas M, Cassaigne A, et al. Common and rare genotypes of human apolipoprotein E determined by specific restriction profiles of polymerase chain reaction-amplified DNA. Clin Chem 1994; 40: 24-29.
22. Srinivasan SR, Ehnholm C, Wattigney WA, Bao W, Berenson GS. The relation of apolipoprotein E polymorphism to multiple cardiovascular risk in children: The Bogalusa Heart Study. Atherosclerosis 1996; 123: 33-42.
23. Tan CE, Tai ES, Tan CS, Chia KS, Lee J, Chew SK, et al. Apolipoprotein E polymorphism and lipid profile in three ethnic groups in the Singapore population. Atherosclerosis 2003; 170: 253-260.
24. Liu S, Ma J, Ridker PM, Breslow JL, Stampfer MJ. A prospective study of the association between APOE genotype and the risk of myocardial infarction among apparently healthy men. Atherosclerosis 2003; 166: 323-329.
25. Aouizerat BE, Allayee H, Bodnar J, Krass KL, Peltonen L, de Bruin TW, et al. Novel genes for familial combined hyperlipidemia. Curr Opin Lipidol 1999; 10: 113-122.
26. Dallinga-Thie GM, van Linde-Sibenius Trip M, Rotter JI, Cantor RM, Bu X, Lusis AJ, et al. Complex genetic contribution of the apoA1-C3-A4 gene cluster to familial combined hyperlipidemia: Identification of different susceptibility haplotypes. J Clin Invest 1997; 99: 953-961.
27. Allayee H, Castellani LW, Cantor RM, de Bruin TW, Lusis AJ. Biochemical and genetic association of plasma apolipoprotein A-II levels with familial combined hyperlipidemia. Circ Res 2003; 92: 1262-1267.
28. Aouizerat BE, Allayee H, Cantor RM, Dallinga-Thie GM, Lanning CD, de Bruin TW, et al. Linkage of a candidate gene locus to familial combined hyperlipidemia. Lecithin: Cholesterol Acyltransferase on 16q. Arterioscler Thromb Vasc Biol 1999; 19: 2730-2736.
29. Houlston R, Lewis B, Humphries SE. Polymorphisms of the apolipoprotein B and E genes and their possible roles in familial and non-familial combined hyperlipidemia. Dis Markers 1991; 9: 319-325.
30. Kao JT, Tsai KS, Chang CJ, Huang PC. The effects of apolipoprotein E polymorphism on the distribution of lipids and lipoproteins in the Chinese population. Atherosclerosis 1995; 114: 55-59.
31. Kuusisto J, Mykkanen L, Kervinen K, Kesaniemi YA, Laakso M. Apolipoprotein E4 phenotype is not an important risk factor for coronary heart disease or stroke in elderly subjects. Arterioscler Thromb Vasc Biol 1995; 15: 1280-1286.
32. Kamboh MI, Aston CE, Hamman RF. The relationship of APOE polymorphism and cholesterol levels in normoglycemic and diabetic subjects in biethnic population from the San Lusis Valley, Colorado. Atherosclerosis 1995; 112: 145-159.
33. Hanis CL, Hewett-Emmett D, Douglas TC, Bertin TK, Schull WJ. Effects of the apolipoprotein E polymorphism on levels of lipids, lipoproteins, and apolipoproteins among Mexican-Americans in Starr County, Texas. Arterioscler Thromb 1991; 11: 362-370.
34. Feitosa MF, Rice T, North KE, Kraja A, Rankinen T, Leon AS, et al. Pleiotropic QTL on chromosome 19q13 for triglycerides and adiposity: The HERITAGE family study. Atherosclerosis 2006; 185: 426-432.
35. Khoo KL, Tan H, Liew YM, Deslypere JP, Janus E. Lipids and coronary heart disease in Asia. Atherosclerosis 2003; 169: 1-10.
36. Veerkamp MJ, de Graaf J, Bredie SJ, Hendriks JC, Demacker PN, Stalenhoef AF. Diagnosis of familial combined hyperlipidemia based on lipid phenotype expression in 32 families: Results of a 5-year follow-up study. Arterioscler Thromb Vasc Biol 2002; 22: 274-282.
37. Ayyobi AF, McGladdery SH, McNeely MJ, Austin MA, Motulsky AG, Brunzell JD. Small, dense LDL and elevated apolipoprotein B are the common characteristics for the three major lipid phenotypes of familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol 2003; 23: 1289-1294.
38. Islam S, Gutin B, Manos T, Smith C, Treiber F. Low density lipoprotein cholesterol/apolipoprotein B-100 ratio: Interaction of family history of premature atherosclerotic coronary artery disease with race and gender in 7 to 11 year olds. Pediatrics 1994; 94: 494-499.
39. Sniderman AD, Castro Cabezas M, Ribalta J, Carmena R, de Bruin TW, de Graaf J, et al. A proposal to redefine familial combined hyperlipidaemia: 3rd workshop on FCHL held in Barcelona, 3-5 May 2001, during the scientific sessions of the European Society for Clinical Investigation. Eur J Clin Invest 2002; 32: 71-73.